Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad A. Ghamande, John K. Chan, Minal A. Barve, Jonathan Oh, Devansu Tewari, Peter C. Morris, Erin E. Stevens, Justin N. Bottsford-Miller, Min Tang, Phylicia Aaron, Laura Stanbery, Staci Horvath, Gladice Wallraven, Ernest Bognar, Luisa Manning, John Nemunaitis, David Shanahan, Brian M. SlomovitzThomas J. Herzog, Bradley J. Monk, Robert L. Coleman

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences